In this study, we used strain-resolved metagenomic classification to discover a signature of 22 gut microbial strains associated with response to combination ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) in a phase 2 trial cohort of Australian patients with diverse rare cancers (n = 106). This evidence concerns the gene CTLA4 and cancer.